Global Health Updates: From New Cancer Treatments to IPO Insights
The report covers significant health news such as the FDA approval for an injectable cancer drug, Anthem Biosciences' IPO filing, bird flu outbreaks in France, and China's stance on COVID-19 data sharing. It also discusses lawsuits, advances in gene therapy, and planned medication price increases in the U.S.
The FDA has sanctioned an injectable form of Bristol Myers Squibb's cancer drug, Opdivo, as the agency continues to push the frontier of immune system-enhancing therapies known as PD-1 inhibitors.
In a significant financial move, Indian drugmaker Anthem Biosciences seeks to raise $397 million through an IPO, riding the momentum of a robust year for market listings. Key investors include True North and DavosPharma.
France loses its bird flu disease-free status following outbreaks on two poultry farms, reflecting a broader European trend. Meanwhile, China maintains its commitment to COVID-19 transparency amid WHO's calls for enhanced data sharing.
(With inputs from agencies.)
- READ MORE ON:
- FDA
- Opdivo
- cancer drug
- Anthem Biosciences
- IPO
- bird flu
- China
- COVID-19
- Hain Celestial
- Novartis
ALSO READ
Australia Secures Strategic Ties with Solomon Islands Amid China's Rising Influence
China Stocks See Gains Amid Sino-U.S. Tech Tensions
Gem-Studded Debut: International Gemmological Institute's IPO Soars on Market Debut
Britain and China Resume Critical Economic Talks After Long Hiatus
Revival of Australian Lobster Exports to China: A Diplomatic Milestone